Participants
SCLC, tumor, pleural effusion, allergic, ascites, allergy, respiratory syndrome
PLEURAL EFFUSION, TUMOR, ASCITES, SCLC, ALLERGY, ONCOLOGY
Inclusion criteria were: (1) 18 to 75 years old; (2) proven with ES-SCLC by histopathological examination; (3) treatment with standard first-line Etoposide-platinum solely chemotherapy, without progression; (4) Eastern Cooperative Oncology Group (ECOG) performance status of 0–1; (5) one or more computed tomography (CT) measurable lesions; (6) expected survival of at least 3 months; (7) major organ function indicators meeting the following criteria 7 days before the start of treatment: (a) hemoglobin (Hb) ≥ 90 g/L, (b) absolute neutrophil count (ANC) ≥ 1.5 × 10Exclusion criteria were: (1) presence of tumor types other than SCLC and mixed-SCLC; (2) a history of severe allergy or allergic constitution; (3) pregnant or breastfeeding women; (4) participation in other clinical trials; (5) pleural effusion or ascites that induced respiratory syndrome (CTCAE grade 